Krystal Biotech Reports 143% Q2 Profit Surge on Global VYJUVEK Expansion

Krystal Biotech reported strong financial results for the second quarter of fiscal 2025, exceeding earnings per share and revenue estimates with GAAP earnings of $1.29 per share and revenues of $96 million, representing double-digit year-over-year growth. The company is advancing its global expansion with regulatory approvals for its lead gene therapy, VYJUVEK, in Europe and Japan, along with planned launches in Germany and France. Financial robustness is supported by $820 million in cash reserves and a return to revenue growth driven by resumed patient treatments and an expanding sales team. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating and $240 price target, citing Krystal's strong performance and pipeline progress in oncology and aesthetics with upcoming clinical catalysts. Despite recent stock underperformance relative to the S&P 500, Krystal's outlook remains positive due to its expanding commercial footprint and diversified gene therapy pipeline. These results and strategic developments collectively reinforce a favorable long-term growth outlook for the company.